跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 12,110 条关于
“CXCR4 receptor”
全部
12,110
临床试验
5,783
药物
1,362
机构
30
资讯
4,935
去年
EMA Validates Marketing Authorization Application for Mavorixafor in WHIM Syndrome Treatment
2年前
FDA Approves XOLREMDI (mavorixafor) as First Targeted Therapy for WHIM Syndrome
7个月前
European Regulators Recommend Approval of First WHIM Syndrome Treatment
去年
Mavorixafor Advances in Europe for WHIM Syndrome Treatment Following Positive Phase 3 Results
去年
Pentixapharm Pivots Clinical Strategy to Focus on CXCR4-Targeted Theranostic Oncology Platform
去年
X4 Pharmaceuticals Announces Positive Phase 2 Results for Mavorixafor in Chronic Neutropenia
去年
Pentixapharm's Lu177-PentixaTher Enters Phase I/II Trial for AML and ALL
去年
Pentixapharm's Ga68-PentixaFor Receives EMA PRIME Status for Primary Aldosteronism Diagnosis
去年
Exicure Secures Australian Patent for Novel Cancer Treatment Targeting CXCR4 and GPCRx
去年
NCI and NIDDK Initiate Phase II Trial of PentixaFor for Adrenal Tumor Subtyping
第 1 页,共 494 页
上一页
下一页